These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3284118)

  • 1. Cyclosporine A administration: once a day or in fractional doses?
    Dieperink H; Leyssac PP; Starklint H; Kemp E
    Transplant Proc; 1988 Apr; 20(2 Suppl 2):703-6. PubMed ID: 3284118
    [No Abstract]   [Full Text] [Related]  

  • 2. Renal dysfunction in animal models of cyclosporine toxicity.
    Paller MS; Murray BM
    Transplant Proc; 1985 Aug; 17(4 Suppl 1):155-9. PubMed ID: 3895656
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjunctive azathioprine and antilymphocyte serum immunosuppression with cyclosporine.
    Ford HR; Fryd DS; Canafax DM; Ascher NL; Dunn D; Sutherland DE; Najarian JS; Simmons RL
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):8-12. PubMed ID: 3291316
    [No Abstract]   [Full Text] [Related]  

  • 4. Intravenous cyclosporine to induce immunosuppression in cardiac allograft recipients.
    Macris MP; Frazier OH; Van Buren CT; Duncan JM
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):311-5. PubMed ID: 3291261
    [No Abstract]   [Full Text] [Related]  

  • 5. First month cyclosporine A sparing in renal transplantation.
    Segoloni GP; Messina M; Colla L; Piccoli GB; Triolo G; Vercellone A
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):233-8. PubMed ID: 3291249
    [No Abstract]   [Full Text] [Related]  

  • 6. Late cyclosporine conversion carries risk of irreversible rejection.
    Sagalowsky AI; Reisman ME; Dawidson I; Toto R; Peters PC; Helderman JH
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):157-60. PubMed ID: 3291233
    [No Abstract]   [Full Text] [Related]  

  • 7. A prospective study of conversion from cyclosporine to azathioprine: comparison of clinical and morphologic findings.
    Abbud-Filho M; Ramalho HJ; Barberato JB; Corrente JE; Salgueiro MC; Mazzetto MR; Bezas AG
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):164-8. PubMed ID: 3291235
    [No Abstract]   [Full Text] [Related]  

  • 8. Correlation of blood levels and tissue levels of cyclosporine with the histologic features of cyclosporine toxicity.
    Kumar MS; White AG; Alex G; Antos MS; Philips EM; Abouna GM
    Transplant Proc; 1988 Apr; 20(2 Suppl 2):407-13. PubMed ID: 3363646
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevention of nephrotoxic cyclosporine peak concentrations by daily drug division in 3 equal oral portions.
    Zazgornik J; Schindler J; Balcke P; Kopsa H; Gremmel F; Derfler K; Kretschmer G; Mühlbacher F; Piza F
    Int J Clin Pharmacol Ther Toxicol; 1987 Apr; 25(4):197-200. PubMed ID: 3294613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential use of antithymocyte globulin and cyclosporine augments skin allograft survival.
    Thomas J; Whitley T; Carver M; Thomas F
    Transplant Proc; 1984 Dec; 16(6):1522-4. PubMed ID: 6390858
    [No Abstract]   [Full Text] [Related]  

  • 11. Is withdrawal of steroids hazardous to cadaveric renal transplants under treatment with cyclosporine?
    Hillebrand G; Krumme D; Schleibner S; Land W; Gurland HJ
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):126-9. PubMed ID: 3291225
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of a low-dose two-drug regimen of oral cyclosporine and delayed alternate day prednisone for immunosuppression in cadaver kidney transplantation.
    Belitsky P; MacDonald A; Cohen A; VGivner M; Sketris I
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):78-81. PubMed ID: 3291314
    [No Abstract]   [Full Text] [Related]  

  • 13. Management and prevention of cyclosporine nephrotoxicity after renal transplantation: use of low doses of cyclosporine, azathioprine, and prednisone.
    Simmons RL; Canafax DM; Strand M; Ascher NL; Payne WD; Sutherland DE; Najarian JS
    Transplant Proc; 1985 Aug; 17(4 Suppl 1):266-75. PubMed ID: 3895665
    [No Abstract]   [Full Text] [Related]  

  • 14. Cyclosporine A: effectiveness and toxicity in a rat model.
    Dieperink H; Kemp E; Leyssac PP; Starklint H
    Clin Nephrol; 1986; 25 Suppl 1():S46-50. PubMed ID: 3519030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is cyclosporine A-induced nephrotoxicity in recipients of renal allografts progressive?
    Thiel G; Mihatsch M; Landmann J; Hermle M; Brunner FP; Harder F
    Transplant Proc; 1985 Aug; 17(4 Suppl 1):169-78. PubMed ID: 3895657
    [No Abstract]   [Full Text] [Related]  

  • 16. Experimental cyclosporine nephrotoxicity: risk of concomitant chemotherapy.
    Ryffel B; Müller AM; Mihatsch MJ
    Clin Nephrol; 1986; 25 Suppl 1():S121-5. PubMed ID: 3708922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of infusion duration on the efficacy and toxicity of intravenous cyclosporine in bone marrow transplant patients.
    McGuire TR; Tallman MS; Yee GC; Nemunaitis JJ; Higano CS; McGuffin RW; Singer JW
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):501-4. PubMed ID: 3291288
    [No Abstract]   [Full Text] [Related]  

  • 18. Cyclosporine chronic nephrotoxicity: histologic follow-up at 6 and 18 months after renal transplantation.
    Savoldi S; Scolari F; Sandrini S; Scaini P; Sacchi G; Tardanico R; Camerini C; Salerni B; Tonini G; De Nobili U
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):777-84. PubMed ID: 3291313
    [No Abstract]   [Full Text] [Related]  

  • 19. Cyclosporin A administration in dermatology: once a day or in fractional doses?
    Korstanje MJ
    Arch Dermatol Res; 1990; 281(8):536-7. PubMed ID: 2322012
    [No Abstract]   [Full Text] [Related]  

  • 20. Conversion of immunosuppression in renal allograft recipients from cyclosporine A to azathioprine and prednisolone 6 months after transplantation.
    Lennard TW; Venning M; Donnelly PK; Wilson RG; Parrott NR; Elliott RW; Proud G; Farndon JR; Ward MK; Wilkinson R
    Transplant Proc; 1987 Oct; 19(5):3594-6. PubMed ID: 3313866
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.